Medtronic Receives FDA Approval for Percept™ RC DBS System

Medtronic has received the U.S. FDA approval for Percept™ RC Deep Brain Stimulation (DBS) system, a rechargeable neurostimulator that is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology, and SenSight™ directional leads.

The Percept™ family is the only sensing-enabled DBS system on the market that allows physicians to personalize treatment for patients with movement disorders such as Parkinson’s disease, essential tremor, and dystonia as well as epilepsy. Percept™ RC is the smallest and thinnest dual channel neurostimulator available for DBS. It is equipped with BrainSense™ technology, which captures and records brain signals to provide insights that enable a healthcare provider to adapt and personalize therapy to a patient’s evolving needs. Unlike other rechargeable devices, the Percept™ RC battery offers at least 15 years of service life with consistent and fast recharge performance.

Medtronic was the first company in the United States to offer full-body MR conditional DBS systems, which allow patients to be safely scanned anywhere on the body under certain conditions. Percept™ offers greater freedom and scan access for patients with 3T scans and best-in-class 1.5T MRI scan labelling. Medtronic has the only DBS system that allows patients to receive stimulation in bipolar mode during an MRI.

Our DBS therapy with exclusive BrainSense™ technology can help control debilitating tremors for people living with Parkinson’s, providing patients with the ability to physically engage in everyday moments – something many of us unintentionally take for granted,” said Amaza Reitmeier, VP and general manager, Brain Modulation at Medtronic.

To view the source version, please click HERE.